Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 30, 2011

Latent tuberculosis vaccine enters clinical testing

Non-profit product development partnership Aeras has announced the start of a Phase I clinical trial of a new candidate tuberculosis vaccine, designed specifically to protect against the latent form of the disease.

By Liam Stoker

 

Non-profit product development partnership Aeras has announced the start of a Phase I clinical trial of a new candidate tuberculosis vaccine, designed specifically to protect against the latent form of the disease.

The clinical trial is the first to test the vaccine in humans following pre-clinical studies in latently infected animals.

The vaccine is being developed by Aeras and Statens Serum Institut (SSI)

In pre-clinical trials the vaccine demonstrated no safety concerns, and was also shown to control clinical disease and reactivation in a non-human primate model.

The trial will involve 25 adults, both with and without latent tuberculosis, and will be conducted by the South African Tuberculosis Vaccine Initiative (SATVI) at its field site in Worcester, Western Cape, South Africa.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

SSI vice-president of vaccine R&D Professor Peter Andersen said: "The advancement of this candidate from an idea to the clinic working in collaboration first with the Grand Challenges consortium and now with Aeras and SATVI is an important and exciting milestone for all the researchers involved."

Preliminary results of the trial are expected at the end of 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU